中国高端医疗设备产业迎来历史性时刻，在超高端医疗装备领域正式跻身全球第一阵营。 据国家药监局官网8月26日消息，由联影医疗自主研发的中国首款光子计数能谱CT uCT Ultima正式获得 国家药品监督管理局（NMPA）批准上市。联影医疗成为全球范围内，首家成功实现光子计数能谱CT 商业化的中国企业。 2025年全球光子计数CT市场规模约20亿美元，联影医疗与东软医疗光子计数CT的同步获批，形成了"技 术路线互补+市场定位协同"的双龙头格局。 "此次国产光子计数CT的获批，不仅是技术层面的'从0到1'突破，更是国产高端影像设备从'替代'走 向'引领'的关键转折。"该分析师强调。实现技术革命 光子计数CT被誉为医疗设备领域"皇冠上的明珠"，是CT发展的"第三次技术革命"。 与传统CT相比，光子计数CT的优势可以用从"黑白照片"到"彩色照片"的飞跃来形象概括。 联影医疗计算机断层扫描事业部总裁杜岩峰对21世纪经济报道记者介绍，传统CT通过闪烁体探测器首 先把X射线转化成可见光，然后利用光电二极管把可见光转化成电子信号进行间接探测，由于探测器响 应速度慢和信噪比低，丢失了单个X射线的能量信息，因此拍出的片子相当于"黑 ...

21世纪经济报道季媛媛 中国高端医疗设备产业迎来历史性时刻，在超高端医疗装备领域正式跻身全球第一阵营。 据国家药监局官网8月26日消息，由联影医疗自主研发的中国首款光子计数能谱CT uCT Ultima正式获得 国家药品监督管理局（NMPA）批准上市。联影医疗成为全球范围内，首家成功实现光子计数能谱CT 商业化的中国企业。 与此同时，东软医疗自主研发的NeuViz P10碲锌镉光子计数CT正式获得国家药品监督管理局批准上 市。这也是全球首台8cm宽体光子计数CT。 光子计数能谱CT一直是备受行业关注的下一代CT技术的革命方向。相比于传统CT，光子计数CT搭载 了半导体探测器，具有更高空间分辨率成像、直接多能谱成像以及更低辐射剂量成像的优势，极大程度 推进了精准诊疗。然而囿于高筑的技术壁垒，此前全球范围内仅有两家外资企业实现了光子计数能谱 CT的商业化。 这两项突破标志着中国在下一代CT技术领域实现了从"跟跑"到"领跑"的跨越。 有券商分析师对21世纪经济报道记者表示，目前全球范围内仅西门子医疗（2021年获批）、GE医疗 （2023年获批）推出了临床级光子计数CT，但均为"小探测器（≤4cm）+单源"配置，主 ...

分型精准治疗为代表的治疗理念，大大提升了患者预后，已成为晚期乳腺癌的主流治疗理念。殷咏梅表 示，目前针对PAM通路突变的一些靶向药物联合内分泌治疗，已经在后续治疗上发挥了很大的作用。 "HR+/HER2-乳腺癌患者如果能够早期诊断、早期治疗，预后比较好，但部分患者确诊时已经是局部晚 期，有20%-30%的复发可能性。"殷咏梅表示，过去缺乏内分泌治疗的靶向药物，这部分人群五年生存 率只有20%-30%。在CDK4/6抑制剂问世后，五年生存率有所提升，但部分晚期乳腺癌患者会对CDK4/6 抑制剂和目前的内分泌疗法产生耐药。 "一旦出现耐药，患者的预后会很差。对于这部分患者而言，是否有更好的治疗药物，是目前我们最关 心的问题。"殷咏梅提及，内分泌治疗原发耐药患者中，约60%以上可能会有PAM通路的突变，尤其是 早复发的患者，即辅助治疗期间出现复发和转移，或者在辅助治疗五年结束以后还不到一年之内复发的 患者。PAM通路的突变，会对肿瘤的发生、进展等方面产生促进作用。因此，内分泌治疗发生耐药 后，最关键的是尽早做PAM通路基因检测。针对PAM通路上有相关突变的，后续就会根据患者的检验 结果进行更精准的治疗。 新京报讯( ...

Core Insights - The company, Lanwei Medical, provides third-party medical testing and pathology diagnosis services, as well as well-known domestic and international in vitro diagnostic products and research technical services to various medical institutions and research institutes [1][2] - The chairman and general manager, Zeng Weixiong, emphasized the company's commitment to high-quality development guided by precision diagnosis and treatment, leveraging its self-built precision medicine center and research innovation center [1] Group 1 - The company aims to enhance its operational capabilities and improve the efficiency of core service processes [1] - It plans to upgrade the network layout and standardized management of regional testing centers [1] - The company is focused on empowering grassroots healthcare by promoting high-quality medical resources and services [1] Group 2 - Lanwei Medical is positioned as a comprehensive service provider offering integrated solutions for the medical diagnostics industry, ranking among the industry leaders [2] - The company addresses the differentiated needs of its clients through a variety of specialized technical support [2]

Core Viewpoint - Lanwei Medical reported a revenue of 1.74 billion yuan for 2024, reflecting a year-on-year growth of 4.1%, while the loss narrowed to 109 million yuan, indicating an improvement in operational conditions [1] Group 1: Financial Performance - The company achieved a revenue of 797 million yuan from medical diagnostic services, marking a year-on-year increase of 23.26%, driven by business expansion in various cities and growth in CRO and research service revenues [1] - The revenue from in vitro diagnostic product sales was 945 million yuan, showing a decline of 7.46%, attributed to intensified market competition and related policy impacts [2] Group 2: Business Strategy - Lanwei Medical plans to enhance its business model through a combination of product agency and third-party services, aiming to enrich its commercial structure and expand its marketing network [2] - The company aims to focus on precision diagnosis, leveraging its self-built precision medicine center and research innovation center to collaborate with key clients in establishing high-end joint laboratories [3] Group 3: Future Development Plans - The company intends to strengthen its digital innovation capabilities to drive dual business development, with increased investment in technology related to oncology and reproductive genetics [3] - Lanwei Medical will enhance its ecological industrial chain layout by integrating resources such as biobanks and pathology diagnostics, providing standardized laboratory solutions and comprehensive health data support [3][4] - The company aims to build a professional research service team to improve delivery capabilities and enhance market competitiveness through systematic training and management upgrades [4]